跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD33 CAR-T
首页
药物
CD33 CAR-T
CD33 CAR-T
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3
US 2023330139 A1
申请人: AUTOLUS LTD
优先权: 2018
CN
EP
US
WO
8 件公开
Treatment of cancer using a CD33 chimeric antigen receptor
US 9777061 B2
申请人: NOVARTIS AG
优先权: 2014
CN
EP
US
7 件公开
BISPECIFIC IN TANDEM RECEPTOR CAR AND METHOD FOR MODULATING THE TUMORAL MICROENVIRONMENT
EP 3908613 A4
申请人: CELLURIS PARTICIPACOES LTDA
优先权: 2019
EP
US
WO
5 件公开
CD70 BINDING CAR-T CELLS COMPRISING CD33 BINDING T-CELL ENGAGING ANTIBODY MOLECULES
EP 4507706 A4
申请人: MASSACHUSETTS GEN HOSPITAL
优先权: 2022
CN
EP
US
WO
4 件公开
Compositions and methods for targeting CD33-expressing cancers
US 11479606 B2
申请人: H LEE MOFFITT CANCER CT & RES
优先权: 2018
US
3 件公开
INHIBITORY CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF
US 20260115290 A1
申请人: UNIV OF SOUTHERN CALIFORNIA
优先权: 2021
US
WO
2 件公开
Components and methods for treating acute myelogenous leukemia
CN 116850210 A
申请人: UNIV WUHAN
优先权: 2023
CN
2 件公开
抗CD33嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
CN 105820255 B
申请人: 上海优卡迪生物医药科技有限公司
优先权: 2016
CN
CD33 immunogenic polypeptide and application thereof
CN 106336456 A
申请人: SUZHOU PULUODA BIOLOGICAL SCIENCE AND TECH CO LTD
优先权: 2016
CN
COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD33 IMMUNOTHERAPY
WO 2018175988 A1
申请人: LENTIGEN TECH INC
优先权: 2017
WO
第 1 / 3 页
上一页
下一页
药物
反馈